Tenax Therapeutics, Inc. (Nasdaq: TENX), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that it will participate in the 36th Annual Roth Conference in Dana Point, California, from March 17-19, 2024. Tenax’s CEO, Chris Giordano, will provide an update on the company and the ongoing development of levosimendan, in a conference session investors can attend in person, or via webcast.

Format: Fireside Chat Presenter: Chris Giordano, President & Chief Executive OfficerDate and time: March 18, 2024 at 3:00 pm PDT Location: The Ritz-Carlton, Laguna NiguelWebcast: Click here

Tenax Therapeutics’ management will also participate in one-on-one investor meetings. Attendees may request meetings during the conference by contacting their Roth representative.

The live and archived webcast of the presentation will be accessible from the Company’s investor relations webpage.

About Tenax Therapeutics

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need. The Company owns global rights to develop and commercialize levosimendan. Tenax also is developing a unique oral formulation of imatinib. For more information, visit www.tenaxthera.com. Tenax’s common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.

Contacts

Investor Contact:John FrauncesManaging DirectorLifeSci Advisors, LLCC: 917-355-2395, or

Brian MullenLifeSci Advisors, LLCC: 203-461-1175

Tenax Therapeutics (NASDAQ:TENX)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024 Plus de graphiques de la Bourse Tenax Therapeutics
Tenax Therapeutics (NASDAQ:TENX)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024 Plus de graphiques de la Bourse Tenax Therapeutics